Michael S Perry Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 day, 18 hours ago
Michael S Perry has an estimated net worth of at least $10.1 million*, as of Sept. 23, 2026. They own 111,459 shares of ARWR stock. They have sold 216,162 shares of ARWR stock since 2021, for an estimated $2.3 million.
Michael S Perry $ARWR SEC Form 4 Insider Trading
Michael S Perry has filed a total of 5 insider trades in $ARWR since 2021. Their most recent trade was a sale of 11,600 shares, made on Aug 18, 2026. Their largest trade was a sale of 16,250 shares, made on Dec 05, 2025. We estimate that they now own 111,459 shares of $ARWR, worth an estimated $7.8 million.
Insider Trading at $ARWR
There have been a total of 223 insider trades reported at $ARWR since 2021, with 3,655 shares purchased and 2.2 million shares sold. The most active insider traders in $ARWR stock have been Christopher Richard Anzalone, Patrick O'Brien, and James C Hamilton. The most recent trade was a sale of 2,000 shares reported by ADEOYE Y OLUKOTUN (None), made on Aug 18, 2026.
History of Insider Stock Trades by Michael S Perry
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
ARWR
|
Sale | 11,600 | Aug 18, 2026 | Aug. 20, 2026, 5:22 p.m. |
|
ARWR
|
Sale | 16,250 | Dec 05, 2025 | Dec. 9, 2025, 7:04 p.m. |
RCEL
|
Sale | 150,000 | Nov 21, 2022 | Nov. 22, 2022, 5:46 p.m. |
|
RCEL
|
Sale | 10,812 | Feb 24, 2022 | Feb. 24, 2022, 8 p.m. |
|
ARWR
|
Sale | 2,628 | Jan 03, 2022 | Jan. 3, 2022, 8 p.m. |
|
ARWR
|
Sale | 1,600 | Jan 03, 2022 | Jan. 3, 2022, 8 p.m. |
|
ARWR
|
Sale | 272 | Jan 03, 2022 | Jan. 3, 2022, 8 p.m. |
|
RCEL
|
Sale | 23,000 | Jun 02, 2021 | June 3, 2021, 8 p.m. |
$ARWR Executives and Stock Owners with Insider Trades
-
Christopher Richard Anzalone, Chief Executive Officer
-
Patrick O'Brien, COO and General Counsel
-
James C Hamilton, Chief Medical Officer
-
Kenneth Allen Myszkowski, Chief Financial Officer
-
Patrick O'Brien, COO
-
Martin Javier San, Chief Medical Officer
-
James C Hamilton, Chief Discovery/Trans Medicine
-
Patrick O'Brien, General Counsel
-
Daniel Joseph Apel, Chief Financial Officer
-
Tracie Oliver, Chief Commercial Officer
-
James Hassard, Chief Commercial Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.